.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,583,117

« Back to Dashboard

Details for Patent: 5,583,117

Title: Acylated uridine and cytidine for elevating tissue uridine and cytidine
Abstract:General methods for delivering exogenous cytidine or uridine to the tissue of an animal comprising the administration of acylated cytidine or acylated uridine, respectively, are disclosed. Methods of treating myocardial infarction and cardiac insufficiency comprising the administration of acylated cytidine or acylated uridine, are also disclosed.
Inventor(s): von Borstel; Reid (Kensington, MD), Bamat; Michael K. (Chevy Chase, MD)
Assignee: Pro-Neuron, Inc. (Rockville, MD)
Filing Date:Oct 25, 1993
Application Number:08/140,475
Claims:1. A method of delivering exogenous uridine to the tissue of an animal, comprising the step of administering to said animal an acyl derivative of uridine, having the formula ##STR6## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of acetic acid, glycolic acid, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, with the proviso that at least one R is not hydrogen, or the pharmaceutically acceptable salt thereof.

2. A method of delivering exogenous cytidine to the tissue of an animal, comprising the step of administering to said animal an acyl derivative of cytidine, having the formula ##STR7## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of acetic acid glycolic acid, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, with the proviso that at least one R is not hydrogen, or the pharmaceutically acceptable salt thereof.

3. A method of treating cardiac insufficiency comprising the step of administering to an animal in need of such treatment an acyl derivative of uridine in an amount to effect such treatment, having the formula ##STR8## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of acetic acid, glycolic acid, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, with the proviso that at least one R is not hydrogen, or the pharmaceutically acceptable salt thereof.

4. A method of treating myocardial infarction comprising the step of administering to an animal in need of such treatment an acyl derivative of uridine in an amount to effect such treatment, having the formula ##STR9## wherein R is H or an acyl group derived from a carboxylic add selected from one or more of the group consisting of acetic acid, glycolic acid, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic add, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, with the proviso that at least one R is not hydrogen, or the pharmaceutically acceptable salt thereof.

5. A method of treating cardiac insufficiency comprising the step of administering to an animal in need of such treatment an acyl derivative of cytidine in an amount to effect such treatment, having the formula ##STR10## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of acetic acid, glycolic add, pyruvic add, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, with the proviso that at least one R is not hydrogen, or the pharmaceutically acceptable salt thereof.

6. A method of treating myocardial infarction comprising the step of administering to an animal in need of such treatment an acyl derivative of cytidine in an amount to effect such treatment, having the formula ##STR11## wherein R is H or an acyl group derived from a carboxylic acid selected from one or more of the group consisting of acetic acid, glycolic add, pyruvic acid, lactic acid, enolpyruvic acid, an amino acid, a fatty acid, lipoic acid, pantothenic acid, succinic acid, fumaric acid, adipic acid, acetoacetic acid, p-aminobenzoic acid, betahydroxybutyric acid, orotic acid, and creatine, with the proviso that at least one R is not hydrogen, or the pharmaceutically acceptable salt thereof.

7. A method as in claim 1 wherein said amino acid is selected from the group consisting of glycine, the L forms of alaninc, valine, leucine, isoleucine, phenylalanine, tyrosine, cysteine, cystine, methionine, tryptophan, aspartic acid, glutamic acid, arginine, lysine, histidine, ornithine, and hydroxylysine.

8. A method as in claim 2 wherein said amino acid is selected from the group consisting of glycine, the L forms of alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, cysteine, cystine, methionine, tryptophan, aspartic acid, glutantic acid, arginine, lysine, histidine, ornithine, and hydroxylysine.

9. A method as in claim 1 wherein said carboxylic acid is a fatty acid having 2-18 carbon atoms.

10. A method as in claim 2 wherein said carboxylic acid is a fatty acid having 2-18 carbon atoms.

11. A method as in claim 9 wherein said acyl derivative of uridine is administered orally.

12. A method as in claim 10 wherein said acyl derivative of cytidine is administered orally.

13. A method as in claim 3 wherein said carboxylic acid is a fatty acid having 2-8 carbon atoms.

14. A method as in claim 3 wherein said acyl derivative of uridine is administered orally.

15. A method as in claim 4 wherein said carboxylic acid is a fatty acid having 2-18 carbon atoms.

16. A method as in claim 4 wherein said acyl derivative of uridine is administered orally.

17. A method as in claim 5 wherein said carboxylic acid is a fatty acid having 2-18 carbon atoms.

18. A method as in claim 5 wherein said acyl derivative of cytidine is administered orally.

19. A method as in claim 6 wherein said carboxylic acid is a fatty acid having 2-18 carbon atoms.

20. A method as in claim 6 wherein said acyl derivative of cytidine is administered orally.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc